MetrioPharm AG Expands Patent Protection for its Lead Compound MP1032 to Japan
Zurich, February 14, 2017. MetrioPharm AG announces that a basic patent has been granted on its lead compound MP1032 in Japan. This expands the list of countries in which MetrioPharm has broad protection for MP1032 from Europe, the USA, Australia, New Zealand, Israel, China, Russia, and South Africa to Japan.
The Japanese patent was effectively granted on January 18, 2017 with the issue of the patent with publication number JP6061081B2.
“The granting of the patent in Japan significantly improves our already strong IP position,” comments Dr. Wolfgang Brysch, CEO of MetrioPharm AG. Currently comprehensive patent protection exists for MP1032 in all major markets. In some countries, the parent application or divisional applications thereof are still pending. “With the triad United States, Europe, and Japan we now have patent protection in the three most important pharmaceutical markets. I am confident that all remaining pending applications of the MP1032 patent family will be granted in due course,” explains Dr. Brysch.
MP1032 targets the molecular activation mechanisms of inflammatory macrophages. These cells drive inflammation, pain and tissue damage in a wide range of inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, musculo-skeletal injuries, and multiple sclerosis.
The lead compound from MetrioPharm's pipeline of patent-protected, small-molecular active substances has strong anti-inflammatory properties and an excellent toxicity profile.
MetrioPharm AG is a biotech company developing an oral and safe therapy for chronic immune disorders. Our focus is on Immune-mediated Inflammatory Diseases (IMIDs) such as psoriasis, arthritis and multiple sclerosis. MetrioPharm's lead compound MP1032 is currently in phase II clinical testing.
MetrioPharm AG was founded in 2007. The company is headquartered in Zurich and operates a research facility in Berlin.